Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide

Annals of Allergy, Asthma and Immunology

Volumn 91, Issue 3, 2003, Pages 309-313

  Buchvald, Frederik ^a   Bisgaard, Hans ^a,b  

^a Rigshospitalet   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; MONTELUKAST; NITRIC OXIDE; SALMETEROL;

ADOLESCENT; ARTICLE; ASTHMA; CHEWABLE TABLET; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRY POWDER; EXHALATION; EXPIRED AIR; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STEROID THERAPY; TREATMENT OUTCOME;

EID: 0141545046     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63536-3     Document Type: Article

References (29)

1. Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr. 2001;138:694-698.
2. 2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med. 1999;160:1493-1499.
3. 2-agonists in management of childhood asthma: a critical review of the literature [see comments]. Pediatr Pulmonol. 2000;29:221-234.
4. Jones SL, Kittelson J, Cowan JO, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med. 2001;164:738-743.
5. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152:1107-1136.
6. Kharitonov S, Alving K, Barnes PJ, The European Respiratory Society Task Force. Exhaled and nasal nitric oxide measurements: recommendations. Eur Respir J. 1997;10:1683-1693.
7. Bisgaard H, Loland L, Anhoj J. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med. 1999;160:1227-1231.
8. 2-adrenoceptor genotype. Am J Med. 2000;109:114-121.
9. Wilson AM, Dempsey OJ, Sims EJ, et al. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest. 2001;119:1021-1026.
10. Bratton DL, Lanz MJ, Miyazawa N, et al. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: a preliminary study. Pediatr Pulmonol. 1999;28:402-407.
11. Kobayashi H, Takahashi Y, Mitsufuji H, et al. Decreased exhaled nitric oxide in mild persistent asthma patients treated with a leukotriene receptor antagonist, pranlukast. Jpn J Physiol. 1999;49:541-544.
12. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109:410-418.
13. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 1999;130:487-495.
14. Warke TJ, Fitch PS, Brown V, et al. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax. 2002;57:383-387.
15. Mattes J, Storm van's GK, Reining U, et al. NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma. Eur Respir J. 1999;13:1391-1395.
16. Kharitonov SA, Yates DH, Chung KF, et al. Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Eur Respir J. 1996;9:196-201.
17. Beck-Ripp J, Griese M, Arenz S, et al. Changes of exhaled nitric oxide during steroid treatment of childhood asthma. Eur Respir J. 2002;19:1015-1019.
18. Ghiro L, Zanconato S, Rampon O, et al. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J. 2002;20:630-634.
19. Fuglsang G, Vikre-Jorgensen J, Agertoft L, et al. Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. Pediatr Pulmonol. 1998;25:314-321.
20. 2-agonists on exhaled nitric oxide in asthmatic patients. Eur Respir J. 1997;10:1483-1488.
21. 2-agonist inhalation and spirometry in asthma. Am J Respir Crit Care Med. 1999;159:940-944.
22. Kharitonov SA, Barnes PJ. Clinical aspects of exhaled nitric oxide. Eur Respir J. 2000;16:781-792.
23. van Den Toorn LM, Prins JB, Overbeek SE, et al. Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness. Am J Respir Crit Care Med. 2000;162:953-957.
24. Leuppi JD, Downs SH, Downie SR, et al. Exhaled nitric oxide levels in atopic children: relation to specific allergic sensitisation, AHR, and respiratory symptoms. Thorax. 2002;57:518-523.
25. Nielsen KG, Bisgaard H. Bronchodilation and bronchoprotection in asthmatic preschool children from formoterol administered by mechanically actuated dry-powder inhaler and spacer. Am J Respir Crit Care Med. 2001;164:256-259.
26. 1/FVC? Pediatr Pulmonol. 1993;16:19-22.
27. Mostgaard G, Siersted HC, Hansen HS, et al. Reduced forced expiratory flow in schoolchildren with respiratory symptoms: the Odense Schoolchild Study. Respir Med. 1997;91:443-448.
28. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol. 1997;100:44-51.
29. Bousquet J. The relative importance of small airways in asthma. Respir Med. 2000;94(Suppl):S1-S2.